IL-6 variant is associated with metastasis in breast cancer patients.

<h4>Introduction</h4>Although tumor metastases remain significant drivers of mortality, the genetic factors that increase the risks of metastases are not fully identified. Interleukin 6 (IL-6) has emerged as an important factor in breast cancer progression with IL-6 single nucleotide pol...

Full description

Saved in:
Bibliographic Details
Main Authors: Chike O Abana, Brian S Bingham, Ju Hwan Cho, Amy J Graves, Tatsuki Koyama, Robert T Pilarski, A Bapsi Chakravarthy, Fen Xia
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0181725&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841533115154038784
author Chike O Abana
Brian S Bingham
Ju Hwan Cho
Amy J Graves
Tatsuki Koyama
Robert T Pilarski
A Bapsi Chakravarthy
Fen Xia
author_facet Chike O Abana
Brian S Bingham
Ju Hwan Cho
Amy J Graves
Tatsuki Koyama
Robert T Pilarski
A Bapsi Chakravarthy
Fen Xia
author_sort Chike O Abana
collection DOAJ
description <h4>Introduction</h4>Although tumor metastases remain significant drivers of mortality, the genetic factors that increase the risks of metastases are not fully identified. Interleukin 6 (IL-6) has emerged as an important factor in breast cancer progression with IL-6 single nucleotide polymorphism (SNP) variants shown to affect survival. We hypothesized that SNPs of the IL-6 promoter at rs1800795 in breast cancer patients are associated with distant metastases.<h4>Methods</h4>We performed an initial case-control study using Vanderbilt University Medical Center's BioVU, a genomic biobank linked to de-identified electronic medical records in the Synthetic Derivative database, to identify germline SNPs that may predict the development of metastatic disease to any site from any solid tumor including breast cancer. We identified a SNP in IL-6: rs1800795 to be of significance and evaluated this finding using a separate, matched-pair cohort of breast cancer patients with and without metastases from The Ohio State University Wexner Medical Center.<h4>Results</h4>The initial study suggested that GG relative to CG at rs1800795 (OR 1.52; 95% CI 1.14-2.02; p = 0.004) was significantly associated with the development of metastases. This association was also observed in the Ohio State University cohort (OR 2.23; 95% CI 1.06-4.71; p = 0.001). There were no significant relationships between rs1800795 status and any patient or tumor characteristics, including estrogen receptor status.<h4>Conclusions</h4>These findings suggest that GG SNP at IL-6: rs1800795 may indicate an increased risk of metastasis of primary breast cancer. Further studies in larger population sets are warranted as advanced screening and prophylactic intervention might be employed in GG carriers.
format Article
id doaj-art-b4b34ddd36ed49a4a032a885dfe5aa1f
institution Kabale University
issn 1932-6203
language English
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-b4b34ddd36ed49a4a032a885dfe5aa1f2025-01-17T05:32:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01127e018172510.1371/journal.pone.0181725IL-6 variant is associated with metastasis in breast cancer patients.Chike O AbanaBrian S BinghamJu Hwan ChoAmy J GravesTatsuki KoyamaRobert T PilarskiA Bapsi ChakravarthyFen Xia<h4>Introduction</h4>Although tumor metastases remain significant drivers of mortality, the genetic factors that increase the risks of metastases are not fully identified. Interleukin 6 (IL-6) has emerged as an important factor in breast cancer progression with IL-6 single nucleotide polymorphism (SNP) variants shown to affect survival. We hypothesized that SNPs of the IL-6 promoter at rs1800795 in breast cancer patients are associated with distant metastases.<h4>Methods</h4>We performed an initial case-control study using Vanderbilt University Medical Center's BioVU, a genomic biobank linked to de-identified electronic medical records in the Synthetic Derivative database, to identify germline SNPs that may predict the development of metastatic disease to any site from any solid tumor including breast cancer. We identified a SNP in IL-6: rs1800795 to be of significance and evaluated this finding using a separate, matched-pair cohort of breast cancer patients with and without metastases from The Ohio State University Wexner Medical Center.<h4>Results</h4>The initial study suggested that GG relative to CG at rs1800795 (OR 1.52; 95% CI 1.14-2.02; p = 0.004) was significantly associated with the development of metastases. This association was also observed in the Ohio State University cohort (OR 2.23; 95% CI 1.06-4.71; p = 0.001). There were no significant relationships between rs1800795 status and any patient or tumor characteristics, including estrogen receptor status.<h4>Conclusions</h4>These findings suggest that GG SNP at IL-6: rs1800795 may indicate an increased risk of metastasis of primary breast cancer. Further studies in larger population sets are warranted as advanced screening and prophylactic intervention might be employed in GG carriers.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0181725&type=printable
spellingShingle Chike O Abana
Brian S Bingham
Ju Hwan Cho
Amy J Graves
Tatsuki Koyama
Robert T Pilarski
A Bapsi Chakravarthy
Fen Xia
IL-6 variant is associated with metastasis in breast cancer patients.
PLoS ONE
title IL-6 variant is associated with metastasis in breast cancer patients.
title_full IL-6 variant is associated with metastasis in breast cancer patients.
title_fullStr IL-6 variant is associated with metastasis in breast cancer patients.
title_full_unstemmed IL-6 variant is associated with metastasis in breast cancer patients.
title_short IL-6 variant is associated with metastasis in breast cancer patients.
title_sort il 6 variant is associated with metastasis in breast cancer patients
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0181725&type=printable
work_keys_str_mv AT chikeoabana il6variantisassociatedwithmetastasisinbreastcancerpatients
AT briansbingham il6variantisassociatedwithmetastasisinbreastcancerpatients
AT juhwancho il6variantisassociatedwithmetastasisinbreastcancerpatients
AT amyjgraves il6variantisassociatedwithmetastasisinbreastcancerpatients
AT tatsukikoyama il6variantisassociatedwithmetastasisinbreastcancerpatients
AT roberttpilarski il6variantisassociatedwithmetastasisinbreastcancerpatients
AT abapsichakravarthy il6variantisassociatedwithmetastasisinbreastcancerpatients
AT fenxia il6variantisassociatedwithmetastasisinbreastcancerpatients